Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2015

View Archived Issues

ChemoCentryx, a company focusing on chemoattractant receptors, reviews company outlook

Novel synthetic medium-size compounds mimic functions of antibodies

New evidence provided on SEMA4D as a promising target for MS

3SBio acquires contract manufacturer Sirton Pharmaceuticals

PXT-864 pleodrug improves biological AD-related features

RestorGenex compound granted FDA orphan status for glioblastoma multiforme

Aclaris Therapeutics reports data from phase IIb trial of A-101

Actavis to acquire Auden Mckenzie

Hybrigenics extends partnership with Servier for ubiquitin-specific protease inhibitors

Pfizer aims to improve access to Prevenar 13 in poorest countries

Redx Pharma patents Hedgehog signaling pathway inhibitors

Takeda reports development of RORgamma-t antagonists

Anti-IL-32 MAbs described in ImmunoQure patent

Academic researchers prepare and test ALK inhibitors

Abide Therapeutics divulges MGL inhibitors

National University of Singapore presents peptide inhibitors of FXI

NRX-1074 improves depression scores in phase I study

CF-602 shows promise for sexual dysfunction in preclinical studies

Cutanea Life Sciences initiates phase II trial of CLS-003 for cutaneous warts

PlantForm initiates financing round to fund development of biosimilars

Boehringer Ingelheim studies effect of tiotropium and olodaterol Respimat on COPD exacerbations

Forest initiates pediatric phase I/II trial of ceftaroline fosamil

Radius Health initiates phase I trial of RAD-1901 in breast cancer

Amgen and Onyx file applications to expand approval of carfilzomib in the E.U. and U.S.

Janssen closes collaboration and license agreement with MacroGenics for MGD-011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
EASL spotlight: TUNE-401 advances epigenetic silencing in HBV
BioWorld
Several presentations at EASL highlight a new generation of therapies coming into view, with the work from Tune Therapeutics Inc. standing out as one of the most...